Search | Clinical Trials Finder

Conditions: Healthy Volunteer
Interventions: Ethinyl Estradiol + Levonorgestrel, ABBV-722; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Psoriasis
Interventions: ABBV-157, Placebo for ABBV-157; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 10
States / cities: Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 7 more

Conditions: Social Anxiety Disorder
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: The Medical Research Network; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Crohn's Disease, Ulcerative Colitis
Interventions: Risankizumab, Trosunilimab, ABBV-701; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 61
States / cities: Dothan, Alabama • Phoenix, Arizona • Sun City, Arizona + 57 more

Conditions: Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
Interventions: Epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, Venetoclax, Lenalidomide, Pirtobrutinib; Biological · Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 23
States / cities: Birmingham, Alabama • California City, California • Duarte, California + 18 more

Conditions: Healthy Volunteer
Interventions: Tavapadon; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Healthy Volunteers
Interventions: ABBV-903; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL, MCL, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL), Indolent B-cell Non-Hodgkin Lymphoma (iNHL), Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)
Interventions: Epcoritamab; Biological
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 17
States / cities: Phoenix, Arizona • San Francisco, California • Denver, Colorado + 14 more

Conditions: Healthy Volunteer
Interventions: ABBV-552; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Non-Hodgkin's Lymphoma
Interventions: ABBV-291; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Huntersville, North Carolina • Eugene, Oregon • Austin, Texas + 2 more

Conditions: Chronic Hepatitis C Virus (HCV) Infection Genotype 1
Interventions: ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 615 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 48
States / cities: Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 40 more

Conditions: Healthy Volunteers
Interventions: risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Healthy Volunteers
Interventions: Galicaftor, Navocaftor; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Miami, Florida • Grayslake, Illinois

Conditions: Healthy Volunteers
Interventions: Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Cypress, California • Grayslake, Illinois

Conditions: Hidradenitis Suppurativa, Atopic Dermatitis
Interventions: Lutikizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Sacramento, California • Ann Arbor, Michigan

Conditions: Hypogonadism, Testosterone Deficiency
Interventions: ABT-SLV176; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 42
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 37 more

Conditions: Healthy Volunteer
Interventions: ABBV-142, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Rheumatoid Arthritis
Interventions: Placebo, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: Hemet, California • DeBary, Florida • Venice, Florida + 9 more

Conditions: Alzheimer's Disease
Interventions: ABT-354, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Overland Park, Kansas

Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm
Interventions: Venetoclax; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Lymphocytic Leukemia, Chronic
Interventions: Obinutuzumab, Venetoclax; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 7
States / cities: La Jolla, California • Denver, Colorado • New York, New York + 4 more

Conditions: Migraine
Interventions: MEDI0618, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Birmingham, Alabama • Huntsville, Alabama • La Jolla, California + 13 more

Conditions: Psoriasis
Interventions: Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Multiple Myeloma
Interventions: venetoclax, lenalidomide, dexamethasone; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 7
States / cities: Duarte, California • Greenbrae, California • Los Angeles, California + 3 more

Search by objective public record fields.

A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis

Cariprazine Versus Placebo for Social Anxiety Disorder

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants

A Study to Assess the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Adult Volunteers

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants

A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and Navocaftor

A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men

A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants

A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone

Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.

A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy